Accrued Contract Research Costs
Accrued contract research costs
The carrying value as of the balance sheet date of obligations incurred and payable relating to service fees paid to contract manufacturers in connection with the production of clinical drug supplies and to contract research organizations in connection with preclinical studies and clinical trials. Used to reflect the current portion of liabilities (due within one year or within the normal operating cycle if longer).
Accrued Liabilities Current Excluding Accrued Contract Research Costs
Other accrued liabilities
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Excludes accrued contract research costs. (Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Collaboration Revenues [Abstract]
Collaboration revenues:
License and Milestone Revenues
License and milestone revenue
Revenues earned by the entity under collaborative research and development agreements for nonrefundable, up-front license fees and milestone payments, excluding cost sharing reimbursements of research and development costs.
Cost Sharing Reimbursements
Cost sharing reimbursements, net
Reimbursements earned by the entity for costs incurred under collaborative research and development agreements are recognized as cost sharing revenue in the period in which the related research and development costs are incurred. Reimbursements by the entity for agreed-upon costs incurred by partners under collaborative research and development agreements are recognized as a reduction in cost sharing revenue in the period in which the related research and development costs are incurred.
Collaborative Revenues
The aggregate revenue earned under collaborative research and development agreements.
Total collaboration revenues
Total revenues
Total Revenues
Total aggregate revenue earned under collaborative research and development agreements and grants.
The increase (decrease) during the reporting period in collaboration payable.
Collaboration payable
Increase (Decrease) in Collaboration Payable
Increase (Decrease) Accrued Contract and Research Costs
Accrued contract research costs
The increase (decrease) during the reporting period in accrued contract research costs.
Other Accrued Liabilities Disclosure Text Block
Other Accrued Liabilities
The disclosure for accrued liabilities at the end of the reporting period, excluding accrued contract research costs.
License and Development Agreements
Collaborative Development, Commercialization and License Agreement with GSK
Collaborative Arrangement Second Disclosure [Text Block]
Collaborative Development, Commercialization and License Agreement with GSK
The entire disclosure for second collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations there under; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.
Document and Entity Information
Condensed Consolidated Balance Sheets
Statement [Table]
Statement, Scenario [Axis]
Scenario, Unspecified [Domain]
Statement [Line Items]
Statement
Assets [Abstract]
Assets
Assets, Current [Abstract]
Current assets:
Cash and Cash Equivalents, at Carrying Value
Cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Prepaid Expense and Other Assets, Current
Prepaid expenses and other current assets
Assets, Current
Total current assets
Available-for-sale Securities, Current
Marketable securities
Receivables, Long-term Contracts or Programs
Collaboration receivable
Property, Plant and Equipment, Net
Property and equipment, net
Assets
Total assets
Other Assets, Noncurrent
Other assets
Liabilities and Equity [Abstract]
Liabilities and Stockholders' Equity
Liabilities, Current [Abstract]
Current liabilities:
Accounts Payable, Current
Accounts payable
Capital Lease Obligations, Current
Capital lease obligations
Liabilities, Current
Total current liabilities
Secured Debt, Current
Current portion of term loans
Deferred collaboration revenue
Deferred Revenue, Current
Liabilities
Total liabilities
Preferred Stock, Value, Issued
Preferred stock, par value $0.0001 per share Authorized: 5,000,000 shares at September 30, 2011 and December 31, 2010; no shares issued and outstanding at September 30, 2011 and December 31, 2010
Common Stock, Value, Issued
Common stock, par value $0.0001 per share Authorized: 100,000,000 shares at September 30, 2011 and December 31, 2010; 49,498,350 and 42,090,205 shares issued and outstanding at September 30, 2011 and December 31, 2010, respectively
Accumulated Other Comprehensive Income (Loss), Net of Tax
Accumulated other comprehensive income (loss)
Retained Earnings (Accumulated Deficit)
Accumulated deficit
Additional Paid in Capital, Common Stock
Additional paid-in-capital
Liabilities and Equity
Total liabilities and stockholders' equity
Liabilities, Noncurrent [Abstract]
Long-term liabilities:
Capital Lease Obligations, Noncurrent
Capital lease obligations
Deferred Revenue, Noncurrent
Deferred collaboration revenue
Secured Long-term Debt, Noncurrent
Term loans, net of current portion
Liabilities, Noncurrent
Total long-term liabilities
Preferred Stock, Shares Authorized
Preferred stock, shares Authorized
Preferred Stock, Shares Issued
Preferred stock, shares issued
Preferred Stock, Shares Outstanding
Preferred stock, shares outstanding
Common Stock, Par or Stated Value Per Share
Common stock, par value (in dollars per share)
Common Stock, Shares Authorized
Common stock, shares Authorized
Common Stock, Shares, Issued
Common stock, shares issued
Common Stock, Shares, Outstanding
Common stock, shares outstanding
Preferred Stock, Par or Stated Value Per Share
Preferred stock, par value (in dollars per share)
Operating expenses:
Costs and Expenses [Abstract]
General and Administrative Expense
General and administrative
Restructuring Charges
Restructuring
Operating Expenses
Total operating expenses
Research and Development Expense (Excluding Acquired in Process Cost)
Research and development
Earnings Per Share [Abstract]
Net loss per common share:
Earnings Per Share, Basic
Basic net loss per common share (in dollars per share)
Earnings Per Share, Diluted
Diluted net loss per common share (in dollars per share)
Earnings Per Share, Basic and Diluted
Basic and diluted net loss per common share (in dollars per share)
Weighted Average Number of Shares Outstanding, Diluted [Abstract]
Weighted-average common shares outstanding:
Weighted Average Number of Shares Outstanding, Diluted
Diluted weighted average number of common shares outstanding (in shares)
Weighted Average Number of Shares Outstanding, Basic
Basic weighted average number of common shares outstanding (in shares)
Other Nonoperating Income (Expense) [Abstract]
Other (expense) income:
Other Nonoperating Income (Expense)
Other (expense) income, net
Operating Income (Loss)
Loss from operations
Revenue, Net [Abstract]
Revenues:
Grant revenues
Revenue from Grants
Interest Income (Expense), Nonoperating, Net
Interest expense, net
Condensed Consolidated Statements of Operations
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based Compensation
Stock-based compensation expense
Depreciation, Depletion and Amortization
Depreciation and amortization
Increase (Decrease) in Operating Capital [Abstract]
Changes in operating assets and liabilities:
Increase (Decrease) in Restricted Cash for Operating Activities
Restricted cash
Increase (Decrease) in Prepaid Expense and Other Assets
Prepaid expenses and other current assets
Increase (Decrease) in Other Accrued Liabilities
Other accrued liabilities
Increase (Decrease) in Deferred Revenue
Deferred collaboration revenue
Increase (Decrease) in Receivables
Collaboration receivable
Accounts payable
Increase (Decrease) in Accounts Payable, Trade
Increase (Decrease) in Other Noncurrent Assets
Other assets
Payments to Acquire Property, Plant, and Equipment
Purchases of property and equipment
Payments to Acquire Available-for-sale Securities
Purchases of marketable securities
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities
Maturities of marketable securities
Proceeds from Issuance of Secured Debt
Proceeds from term loans
Proceeds from issuance of common stock and exercise of common stock options, net of transaction costs
Proceeds from Issuance or Sale of Equity
Payment of term loans
Repayments of Secured Debt
Repayments of Long-term Capital Lease Obligations
Payment of capital lease obligations
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]
Supplemental disclosure of noncash operating, investing and financing activities:
Acquisition of equipment under capital leases
Capital Expenditures Incurred but Not yet Paid
Supplemental Cash Flow Information [Abstract]
Supplemental disclosure of cash flow information:
Interest Paid
Cash paid for interest
Condensed Consolidated Statements of Cash Flows
Nature of Business
Nature of Operations [Text Block]
Nature of Business
Summary of Significant Accounting Policies
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]
Summary of Significant Accounting Policies
Cash, Cash Equivalents and Marketable Securities
Cash, Cash Equivalents and Marketable Securities
Cash, Cash Equivalents, and Marketable Securities [Text Block]
Fair Value Measurements
Fair Value Disclosures [Text Block]
Fair Value Measurements
Property and Equipment
Property, Plant and Equipment Disclosure [Text Block]
Property and Equipment
Stockholders' Equity
Stockholders' Equity Note Disclosure [Text Block]
Stockholders' Equity
Stock-Based Compensation
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
Stock-Based Compensation
Other Accrued Liabilities
Accounts Payable and Accrued Liabilities Disclosure [Text Block]
Other Accrued Liabilities
Collaborative Arrangement Disclosure [Text Block]
License and Development Agreements
Term Loans
Debt Disclosure [Text Block]
Term Loans
Subsequent Event-Equity Line of Credit
Subsequent Events [Text Block]
Subsequent Event-Equity Line of Credit
Entity Registrant Name
Entity Central Index Key
Document Type
Document Period End Date
Amendment Flag
Amendment Description
Current Fiscal Year End Date
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Filer Category
Entity Public Float
Entity Common Stock, Shares Outstanding
Document Fiscal Year Focus
Document Fiscal Period Focus
Stockholders' equity:
Stockholders' Equity Attributable to Parent [Abstract]
Total stockholders' equity
Stockholders' Equity Attributable to Parent
Net loss
Net loss
Net Income (Loss) Available to Common Stockholders, Basic
Cash flows from operating activities:
Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]
Net cash used in operating activities
Net Cash Provided by (Used in) Operating Activities, Continuing Operations
Cash flows from investing activities:
Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]
Net cash used in investing activities
Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Cash flows from financing activities:
Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]
Net cash provided by financing activities
Net Cash Provided by (Used in) Financing Activities, Continuing Operations
Net decrease in cash and cash equivalents
Net Cash Provided by (Used in) Continuing Operations